Arrowhead Pharmaceuticals(NASDAQ) ARWR

Arrowhead Pharmaceuticals, Inc. makes medicines that stop disease-causing genes. These treatments help people with rare or difficult genetic conditions. The company uses natural cell processes to block harmful proteins.

Turning Off Disease-Causing Genes

• REDEMPLO (plozasiran): Injectable medicine approved to lower triglycerides in adults with familial chylomicronemia syndrome.
• Late-Stage Candidates: Investigational therapies in phase 3 trials for severe hypertriglyceridemia and rare cholesterol disorders.
• Cardiometabolic Pipeline: Various candidates targeting liver fat and obesity through genetic silencing; includes the ARO-INHBE and ARO-ALK7 programs.
• Therapeutic Platform: Proprietary technology used to deliver treatments to tissue types including the liver, lungs, and skeletal muscle.

A Growing Web of Partnerships

• Signed an exclusive licensing agreement with Madrigal Pharmaceuticals in May 2026 for a clinical-stage liver disease treatment.
• Closed a global collaboration with Novartis in October 2025 to develop genetic disease programs for the central nervous system.
• Earned a $200 million milestone payment from Sarepta Therapeutics in Nov. 2025 for reaching clinical trial enrollment targets.
• Received regulatory approvals for REDEMPLO in the United States, European Union, and Australia during fiscal year 2026.

Why the Platform Is Unique

Arrowhead utilizes its proprietary Targeted RNAi Molecule platform to develop therapies with reduced manufacturing costs and flexible administration methods. The company maintains specialized research facilities in California and Wisconsin to support its clinical pipeline and commercial operations.

Recent Financial Performance

• Total revenue reached $75.3 million for the three-month period ended June 30, 2026.
• Market capitalization was $11.7 billion in the third quarter of 2026, up 432.0% year over year.
• Net loss for the nine-month period ended June 30, 2026, was $296.2 million.
• Cash and available-for-sale securities totaled $1.6 billion as of June 30, 2026.

Bottom Line

Arrowhead has transitioned from a research-focused organization to a commercial-stage company following the launch of its first approved product. Its strategy relies on balancing internal development with high-value pharmaceutical partnerships to advance a broad pipeline of genetic medicines.